PL444724A1 - Stabilna nanocząstka polimerowo-lipidowa do wiązania i dostarczania leków, zwłaszcza o właściwościach przeciwnowotworowych oraz sposób wytwarzania stabilnych nanocząstek polimerowo -lipidowych przenoszących leki, zwłaszcza o właściwościach przeciwnowotworowych - Google Patents

Stabilna nanocząstka polimerowo-lipidowa do wiązania i dostarczania leków, zwłaszcza o właściwościach przeciwnowotworowych oraz sposób wytwarzania stabilnych nanocząstek polimerowo -lipidowych przenoszących leki, zwłaszcza o właściwościach przeciwnowotworowych

Info

Publication number
PL444724A1
PL444724A1 PL444724A PL44472423A PL444724A1 PL 444724 A1 PL444724 A1 PL 444724A1 PL 444724 A PL444724 A PL 444724A PL 44472423 A PL44472423 A PL 44472423A PL 444724 A1 PL444724 A1 PL 444724A1
Authority
PL
Poland
Prior art keywords
stable polymer
especially those
cancer properties
drugs
weight
Prior art date
Application number
PL444724A
Other languages
English (en)
Other versions
PL248287B1 (pl
Inventor
Olga Święch
Weronika PIOTROWSKA
Rafał MAĆKIEWICZ
Wojciech Smoron
Mateusz Psurski
Joanna Wietrzyk
Natalia Labędź
Julia WITEK
Original Assignee
Bs Biotechna Spółka Z Ograniczoną Odpowiedzialnością
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bs Biotechna Spółka Z Ograniczoną Odpowiedzialnością filed Critical Bs Biotechna Spółka Z Ograniczoną Odpowiedzialnością
Priority to PL444724A priority Critical patent/PL248287B1/pl
Priority to CN202480044682.8A priority patent/CN121487725A/zh
Priority to IL324424A priority patent/IL324424A/en
Priority to EP24740620.0A priority patent/EP4704817A1/en
Priority to PCT/PL2024/000023 priority patent/WO2024228632A1/en
Publication of PL444724A1 publication Critical patent/PL444724A1/pl
Publication of PL248287B1 publication Critical patent/PL248287B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Przedmiotem zgłoszenia jest stabilna nanocząstka polimerowo-lipidowa do wiązania i dostarczania leków, zwłaszcza o właściwościach przeciwnowotworowych charakteryzująca się tym, że złożona jest z rdzenia zawierającego kwas polimlekowo-ko-glikolowy (PLGA) w ilości od 16,1% do 30,3% wagowych oraz alkohol poliwinylowy (PVA) w ilości od 60,6% do 75,5% wagowych oraz otoczki rdzenia zawierającej mieszankę lipidów: 1,2-dipalmitoilo-sn-glicero-3-fosfocholinę (DDPC) w ilości od 3,66% do 12,6% wagowych, cholesterol w ilości od 1,85% do 6,29% wagowych oraz sól amonową 1,2-distearoilo-sn-glicero-3-fosfoetanoloamina-N –[amino(glikol polietylenowy)-2000 (DSPE-PEG(2000)NH2] w ilości od 0,15% do 0,5% wagowych. Zgłoszenie obejmuje też sposób wytwarzania stabilnych nanocząstek polimerowo-lipidowych przenoszących leki, zwłaszcza o właściwościach przeciwnowotworowych.
PL444724A 2023-05-03 2023-05-03 Stabilna nanocząstka polimerowo-lipidowa do wiązania i dostarczania leków, zwłaszcza o właściwościach przeciwnowotworowych oraz sposób wytwarzania stabilnych nanocząstek polimerowo- lipidowych przenoszących leki, zwłaszcza o właściwościach przeciwnowotworowych PL248287B1 (pl)

Priority Applications (5)

Application Number Priority Date Filing Date Title
PL444724A PL248287B1 (pl) 2023-05-03 2023-05-03 Stabilna nanocząstka polimerowo-lipidowa do wiązania i dostarczania leków, zwłaszcza o właściwościach przeciwnowotworowych oraz sposób wytwarzania stabilnych nanocząstek polimerowo- lipidowych przenoszących leki, zwłaszcza o właściwościach przeciwnowotworowych
CN202480044682.8A CN121487725A (zh) 2023-05-03 2024-05-03 一种用于药物结合与递送尤其是具有抗癌特性药物的结合与递送的稳定聚合物-脂质纳米颗粒以及制备载药尤其是具有抗癌特性药物的稳定聚合物-脂质纳米颗粒的方法
IL324424A IL324424A (en) 2023-05-03 2024-05-03 Stable polymer-lipid nanoparticles for binding and delivering drugs, especially with anticancer properties, and a method for producing stable drug-carrying polymer-lipid nanoparticles, especially with anticancer properties
EP24740620.0A EP4704817A1 (en) 2023-05-03 2024-05-03 Stable polymer-lipid nanoparticle for drug binding and delivery, especially with anticancer properties, and a method for producing stable polymer-lipid nanoparticles carrying drugs, especially with anticancer properties
PCT/PL2024/000023 WO2024228632A1 (en) 2023-05-03 2024-05-03 Stable polymer-lipid nanoparticle for drug binding and delivery, especially with anticancer properties, and a method for producing stable polymer-lipid nanoparticles carrying drugs, especially with anticancer properties

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL444724A PL248287B1 (pl) 2023-05-03 2023-05-03 Stabilna nanocząstka polimerowo-lipidowa do wiązania i dostarczania leków, zwłaszcza o właściwościach przeciwnowotworowych oraz sposób wytwarzania stabilnych nanocząstek polimerowo- lipidowych przenoszących leki, zwłaszcza o właściwościach przeciwnowotworowych

Publications (2)

Publication Number Publication Date
PL444724A1 true PL444724A1 (pl) 2024-11-04
PL248287B1 PL248287B1 (pl) 2025-11-17

Family

ID=91898606

Family Applications (1)

Application Number Title Priority Date Filing Date
PL444724A PL248287B1 (pl) 2023-05-03 2023-05-03 Stabilna nanocząstka polimerowo-lipidowa do wiązania i dostarczania leków, zwłaszcza o właściwościach przeciwnowotworowych oraz sposób wytwarzania stabilnych nanocząstek polimerowo- lipidowych przenoszących leki, zwłaszcza o właściwościach przeciwnowotworowych

Country Status (5)

Country Link
EP (1) EP4704817A1 (pl)
CN (1) CN121487725A (pl)
IL (1) IL324424A (pl)
PL (1) PL248287B1 (pl)
WO (1) WO2024228632A1 (pl)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080286372A1 (en) * 2007-05-16 2008-11-20 Abbott Cardiovascular Systems Inc. Therapeutic compositions for targeted vessel delivery
US20180092854A1 (en) * 2015-03-11 2018-04-05 University Of South Australia Drug delivery composition comprising polymer-lipid hybrid microparticles

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080286372A1 (en) * 2007-05-16 2008-11-20 Abbott Cardiovascular Systems Inc. Therapeutic compositions for targeted vessel delivery
US20180092854A1 (en) * 2015-03-11 2018-04-05 University Of South Australia Drug delivery composition comprising polymer-lipid hybrid microparticles

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FANG DL, CHEN Y, XU B, REN K, HE ZY, HE LL, LEI Y, FAN CM, SONG XR.: "Int J Mol Sci. 2014 Feb 25;15(3):3373-88", DEVELOPMENT OF LIPID-SHELL AND POLYMER CORE NANOPARTICLES WITH WATER-SOLUBLE SALIDROSIDE FOR ANTI-CANCER THERAPY., DOI: 10.3390/ijms15033373 *
GUO Y, BERA H, SHI C, ZHANG L, CUN D, YANG M.: "Acta Pharm Sin B. 2021 Aug;11(8):2565-2584", PHARMACEUTICAL STRATEGIES TO EXTEND PULMONARY EXPOSURE OF INHALED MEDICINES., DOI: 10.1016/j.apsb.2021.05.015 *

Also Published As

Publication number Publication date
CN121487725A (zh) 2026-02-06
EP4704817A1 (en) 2026-03-11
IL324424A (en) 2026-01-01
WO2024228632A1 (en) 2024-11-07
PL248287B1 (pl) 2025-11-17

Similar Documents

Publication Publication Date Title
RU2526114C2 (ru) Липосомы иринотекана или его солей, способ их получения
Young et al. Systematic development of ionizable lipid nanoparticles for placental mRNA delivery using a design of experiments approach
JP5688199B2 (ja) 平滑筋を弛緩させる活性成分を含むリポソーム組成物、その組成物の製造方法、及び治療剤としての用途
EP2344161B1 (en) Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab
US11357724B2 (en) Pharmaceutical composition, preparation and uses thereof
CN110522919A (zh) 甘露糖受体靶向的组合物、药物及其制备方法和应用
CN115708818B (zh) 一种用于雾化吸入脂质纳米粒的通用型处方
JP2017071652A (ja) 疾患修飾性抗リウマチ薬（ｄｍａｒｄ）および抗癌剤としてのメトトレキサートの持続性放出製剤
JP2024527940A5 (pl)
EP4079298A1 (en) Kit for preparing nanoparticle composition for drug delivery, comprising polylactic acid salt
JP2022009657A (ja) リポソーム型イリノテカン及びオキサリプラチンを含む組み合わせ療法を使用して転移性膵臓癌を治療するための方法
MX393126B (es) Composiciones anestesicas de liberacion sostenida, y metodos de preparacion de las mismas
EP2883542B1 (en) Stable oxaliplatin-encapsulating liposome aqueous dispersion and method for stabilizing same
CN106924172A (zh) 一种石杉碱甲溶致液晶制剂及其制备方法
NZ768717A (en) Sustained-release anesthetic compositions and methods of preparation thereof
WO2010104128A1 (ja) ｐＨ応答性リポソーム
CN107714650A (zh) 一种含谷氨酰胺代谢抑制剂脂质体及其药物组合物与用途
Deng et al. Nanoparticle-based delivery systems for synergistic therapy in lung cancers
JP2025504802A (ja) 生分解性ジスルフィド結合を含むイオン化可能な脂質およびこれを含む脂質ナノ粒子
CN109276541B (zh) 一种可调节药物释放的脂质体组合物及其制备方法
PL444725A1 (pl) Kompozycja farmaceutyczna, stosowana w zapobieganiu lub leczeniu chorób nowotworowych i chorób wynikających z nadmiernej proliferacji komórek oraz nanocząsteczka polimerowo-lipidowa zawierająca kompozycję
AU2020349613A1 (en) Immune stimulating micelle composition
CN104023717A (zh) 包括脂质微胶囊递送媒剂的局部调配物和其用途
CN117377467A (zh) 用于制备含有药物且不含两亲聚合物的纳米颗粒的试剂盒
TWI500430B (zh) 伊立替康或鹽酸伊立替康脂質體及其製備方法